Home/Pipeline/Maxigesic® Intranasal Formulation

Maxigesic® Intranasal Formulation

Acute pain

Pre-clinicalEarly Development

Key Facts

Indication
Acute pain
Phase
Pre-clinical
Status
Early Development
Company

About AFT Pharmaceuticals

AFT Pharmaceuticals is a commercial-stage specialty pharma company with a significant presence in Australasia and growing operations in Asia. Its core business model involves licensing and marketing a wide range of pharmaceutical products, while its key growth driver is the global development and commercialization of its patented intravenous and oral analgesic, Maxigesic® (a fixed-dose combination of paracetamol/acetaminophen and ibuprofen). The company has successfully transitioned from a distributor to an innovator, with Maxigesic IV approved and launched in multiple countries and an extensive pipeline of line extensions.

View full company profile

Other Acute pain Drugs

DrugCompanyPhase
VX-548Vertex PharmaceuticalsPhase 3
Maxigesic® Oral TabletsAFT PharmaceuticalsApproved/Commercial
Maxigesic® Rapid (ODT)AFT PharmaceuticalsLaunched